IL1B and glioblastoma: Ketamine has also demonstrated anti-inflammatory potential in vitro, where it was observed to inhibit the production and release of pro-inflammatory cytokines, such as IL-6, IL-1β and TNF-α, in murine macrophages [52], primary rat microglial cells [53] and human-derived glioblastoma cells [54].